Adenoviral Transduction of Mesenchymal Stem Cells: In Vitro Responses and In Vivo Immune Responses after Cell Transplantation
Open Access
- 6 August 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (8) , e42662
Abstract
Adult mesenchymal stem cells (MSCs) are non-hematopoietic cells with multi-lineage potential which makes them attractive targets for regenerative medicine applications. However, to date, therapeutic success of MSC-therapy is limited and the genetic modification of MSCs using viral vectors is one option to improve their therapeutic potential. Ex-vivo genetic modification of MSCs using recombinant adenovirus (Ad) could be promising to reduce undesired immune responses as Ad will be removed before cell/tissue transplantation. In this regard, we investigated whether Ad-modification of MSCs alters their immunological properties in vitro and in vivo. We found that Ad-transduction of MSCs does not lead to up-regulation of major histocompatibility complex class I and II and co-stimulatory molecules CD80 and CD86. Moreover, Ad-transduction caused no significant changes in terms of pro-inflammatory cytokine expression, chemokine and chemokine receptor and Toll-like receptor expression. In addition, Ad-modification of MSCs had no affect on their ability to suppress T cell proliferation in vitro. In vivo injection of Ad-transduced MSCs did not change the frequency of various immune cell populations (antigen presenting cells, T helper and cytotoxic T cells, natural killer and natural killer T cells) neither in the blood nor in tissues. Our results indicate that Ad-modification has no major influence on the immunological properties of MSCs and therefore can be considered as a suitable gene vector for therapeutic applications of MSCs.Keywords
This publication has 38 references indexed in Scilit:
- Murine Mesenchymal Stem Cells Exhibit a Restricted Repertoire of Functional Chemokine Receptors: Comparison with HumanPLOS ONE, 2008
- Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II studyThe Lancet, 2008
- Therapeutic potential of genetically modified mesenchymal stem cellsGene Therapy, 2008
- Mesenchymal Stem Cells Use Integrin β1 Not CXC Chemokine Receptor 4 for Myocardial Migration and EngraftmentMolecular Biology of the Cell, 2007
- Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cellsLeukemia, 2007
- Mesenchymal Stem Cells Are Renotropic, Helping to Repair the Kidney and Improve Function in Acute Renal FailureJournal of the American Society of Nephrology, 2004
- Mesenchymal stem cells: clinical applications and biological characterizationThe International Journal of Biochemistry & Cell Biology, 2004
- Stem cell therapy in a caprine model of osteoarthritisArthritis & Rheumatism, 2003
- Bone Marrow Stromal Stem Cells: Nature, Biology, and Potential ApplicationsStem Cells, 2001
- Multilineage Potential of Adult Human Mesenchymal Stem CellsScience, 1999